September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was recognized by healthcare improvement company Premier Inc. with the Technology Breakthrough Award. Premier’s Technology Breakthrough Award is granted to cutting-edge products that significantly advance healthcare in terms of safety, clinical outcomes and/or operational efficiency.
The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the United States, is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). Cordis, Cardinal Health’s interventional vascular business, is the exclusive U.S. distributor of the Tryton Side Branch Stent.
The Tryton Side Branch Stent System is built using Tri-Zone technology for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
For more information: www.trytonmedical.com
May 13, 2026 
